HALOZYME THERAPEUTICS, INC.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q1+Q2+Q3+Q4) vs FY2024 (Q1+Q2+Q3+Q4)
Revenue
$1.40B
↑+37.6% +$381Mvs FY2024 (Q1+Q2+Q3+Q4)
Gross Profit
$1.17B
↑+36.4% +$312Mvs FY2024 (Q1+Q2+Q3+Q4)
Operating profit
$562M
↑+1.9% +$10Mvs FY2024 (Q1+Q2+Q3+Q4)
Net profit
$458M
↑+3.2% +$14Mvs FY2024 (Q1+Q2+Q3+Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q1+Q2+Q3+Q4) | FY2024 (Q1+Q2+Q3+Q4) |
|---|---|---|
| Revenue | $1.40B | $1.02B |
| COGS | $229M | $159M |
| Gross Profit | $1.17B | $856M |
| R&D | $50M | $79M |
| SG&A | $207M | $154M |
| D&A | $11M | $10M |
| Other OpEx | $338M | $61M |
| Operating Income | $562M | $551M |
| Interest Exp. | $18M | $18M |
| Other Non-Op | $0 | $0 |
| Pretax Income | $544M | $533M |
| Tax | $85M | $89M |
| Net Income | $458M | $444M |
QuarterCharts · SEC EDGAR data · HALO · Comparing FY2025 (Q1+Q2+Q3+Q4) vs FY2024 (Q1+Q2+Q3+Q4)